Table 2.
Follow-up Demographics of the Alzheimer’s Disease Neuroimaging Initiative Cohorta
| Variable | Diagnosis as of January 2011
|
|||||
|---|---|---|---|---|---|---|
| Healthy Control Subject | Healthy Control Subject to MCI | MCI to Healthy Control Subject | MCInp | MCIp | Alzheimer Disease | |
| No. at baseline (No. at 1 y) | 54(50) | 4 (4) | 14 (14) | 218 (175) | 164 (156) | 112 (97) |
| Age, mean (SD), y | 75(6) | 73 (9) | 72 (8) | 75 (8) | 75 (7) | 75 (8) |
| Male-female ratio | 27:27 | 3:1 | 10:4 | 146:72 | 100:64 | 65:47 |
| ApoE allele carrier, % | 7.4 | 25.0 | 28.6 | 44.0 | 67.7 | 67.9 |
| Mini-Mental State Examination score, mean (SD) | 28.9 (1.2) | 29.0 (0.8) | 27.9 (1.6) | 27.2 (1.8) | 26.6 (1.7) | 23.6 (1.9) |
| Cerebrospinal fluid Aβ42 level at baseline, mean (SD), pg/mL | 253 (55) | 238 (4) | 233 (6) | 174 (106) | 147 (86) | 142 (102) |
| PET index of amyloid burden at 1 y, SUVR | 1.23 | No data | 1.57 | 1.56 | 1.79 | 1.71 |
Abbreviations: MCI, mild cognitive impairment; MCInp, patients whose MCI had not yet progressed to dementia; MCIp, patients whose MCI had progressed to dementia; PET, positron emission tomography; SUVR, standard uptake value ratio.
a
The clinical diagnosis at the time of data download (January 2011) was used to calculate demographics for the preliminary progression analysis. Patients may have progressed anywhere between 6 months and 48 months.